SML2720
Miriplatin
>97.5% (Pt analysis)
Synonym(s):
Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate, MPT, SM-11355
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C34H68N2O4Pt
CAS Number:
Molecular Weight:
763.99
UNSPSC Code:
12352200
NACRES:
NA.77
InChI
1S/2C14H28O2.C6H12N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-8H,1-4H2;/q;;-2;+4/p-2/t;;5-,6-;/m..1./s1
InChI key
DTRJSYSQELJDAW-BLUNCNMSSA-L
SMILES string
CCCCCCCCCCCCCC(O[Pt]1(N[C@@H]2CCCC[C@H]2N1)OC(CCCCCCCCCCCCC)=O)=O
assay
>97.5% (Pt analysis)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Miriplatin (SM-11355) is a platinum (II) complex-based anti-neoplastic agent with increased lipophilicity than its family members cisplatin and carboplatin.
Platinum (II) complex-based anti-neoplastic agent with increased lipophilicity than cisplatin and carboplatin.
Storage Class
11 - Combustible Solids
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kenji Ikeda et al.
Hepatology research : the official journal of the Japan Society of Hepatology, 47(7), 632-640 (2016-08-04)
The effect of transcatheter arterial chemoembolization (TACE) is not necessarily sufficient in patients with multiple hepatocellular carcinoma (HCC). We evaluated the antitumor activity and adverse events of TACE using warmed miriplatin suspension for multiple HCC. Seventy patients with multiple HCC
Toru Ishikawa et al.
Molecular and clinical oncology, 5(5), 511-516 (2016-11-25)
Transcatheter arterial chemoembolization (TACE) is the standard therapy for Barcelona Clinic Liver Cancer (BCLC) classification intermediate stage B hepatocellular carcinoma (HCC). However, other transcatheter methods, such as transcatheter arterial infusion (TAI), also play an important role in the treatment of
Shan Liu et al.
Journal of pharmaceutical sciences, 105(1), 78-87 (2016-02-09)
Because of the insolubility of miriplatin in water, miriplatin and lipiodol suspension is the sole formulation of miriplatin approved in Japan to treat hepatocellular carcinoma by transcatheter arterial chemoembolization. Until now, there have been no reports of other pharmaceutical formulations
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service